<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="to severe forms of COVID-19. Keywords COVID-19 Haemophagocytic lymphohistiocytosis HLH" exact="Etoposide" post="Introduction The COVID-19 was declared first by the World"/>
 <result pre="or Ebola frizzled drug) as well as promising malaria drugs" exact="chloroquine" post="and hydroxychloroquine. COVID-19 and haemophagocytic lymphohistiocytosis (HLH) The development"/>
 <result pre="aims at dampening the cytokine storm and is based on" exact="etoposide" post="and dexamethasone with intrathecal methotrexate in case of central"/>
 <result pre="dampening the cytokine storm and is based on etoposide and" exact="dexamethasone" post="with intrathecal methotrexate in case of central nervous system"/>
 <result pre="storm and is based on etoposide and dexamethasone with intrathecal" exact="methotrexate" post="in case of central nervous system involvement [14], [15]."/>
 <result pre="may be due to their rarity or to their under-diagnosis." exact="Etoposide" post="is an ancient cytotoxic agent with predictable side effects"/>
 <result pre="in this fragile sub-group. Additionally, it should be noticed that" exact="Etoposide" post="is a widely used and a relatively cheap medication."/>
 <result pre="progressing with a non-neglectable mortality. The expected therapeutic mechanism of" exact="etoposide" post="Etoposide is a topoisomerase II inhibitor. It has been"/>
 <result pre="with a non-neglectable mortality. The expected therapeutic mechanism of etoposide" exact="Etoposide" post="is a topoisomerase II inhibitor. It has been shown,"/>
 <result pre="hamper antiviral response in human since the combined therapy with" exact="dexamethasone" post="increased the survival of patients with EBV associated HLH"/>
 <result pre="and severe sHLH is the use of the combination of" exact="etoposide" post="and dexamethasone for eight weeks. Age-adjusted doses of Etoposide"/>
 <result pre="sHLH is the use of the combination of etoposide and" exact="dexamethasone" post="for eight weeks. Age-adjusted doses of Etoposide are administered"/>
 <result pre="of etoposide and dexamethasone for eight weeks. Age-adjusted doses of" exact="Etoposide" post="are administered once a week with weekly decisions on"/>
 <result pre="once a week with weekly decisions on whether to continue" exact="etoposide" post="treatment or not, following the clinical and laboratory response"/>
 <result pre="with 2009 influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of" exact="etoposide" post="and dexamethasone in HLH treatment: long-term results of the"/>
 <result pre="influenza A (H1N1) infectionCrit Care152011R8021366922 14BergstenE.HorneA.AricoM.Confirmed efficacy of etoposide and" exact="dexamethasone" post="in HLH treatment: long-term results of the cooperative HLH-2004"/>
 <result pre="report from the HLH study centerMed Pediatr Oncol41200310310912825212 18ImashukuS.KuriyamaK.TeramuraT.Requirement for" exact="etoposide" post="in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisJ Clin"/>
</results>
